97 related articles for article (PubMed ID: 21177839)
1. The impact of using different symptom-based exacerbation algorithms in patients with COPD.
Trappenburg JC; van Deventer AC; Troosters T; Verheij TJ; Schrijvers AJ; Lammers JW; Monninkhof EM
Eur Respir J; 2011 May; 37(5):1260-8. PubMed ID: 21177839
[TBL] [Abstract][Full Text] [Related]
2. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial.
Trappenburg JC; Monninkhof EM; Bourbeau J; Troosters T; Schrijvers AJ; Verheij TJ; Lammers JW
Thorax; 2011 Nov; 66(11):977-84. PubMed ID: 21785156
[TBL] [Abstract][Full Text] [Related]
3. Exacerbations of chronic obstructive pulmonary disease.
Wedzicha JA; Donaldson GC
Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
[TBL] [Abstract][Full Text] [Related]
4. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations.
Xu W; Collet JP; Shapiro S; Lin Y; Yang T; Platt RW; Wang C; Bourbeau J
Am J Respir Crit Care Med; 2008 Nov; 178(9):913-20. PubMed ID: 18755925
[TBL] [Abstract][Full Text] [Related]
5. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
[TBL] [Abstract][Full Text] [Related]
6. How should we define and classify exacerbations in chronic obstructive pulmonary disease?
Trigueros Carrero JA
Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):33-41. PubMed ID: 23551022
[TBL] [Abstract][Full Text] [Related]
7. Colds as predictors of the onset and severity of COPD exacerbations.
Johnston NW; Olsson M; Edsbäcker S; Gerhardsson de Verdier M; Gustafson P; McCrae C; Coyle PV; McIvor RA
Int J Chron Obstruct Pulmon Dis; 2017; 12():839-848. PubMed ID: 28331305
[TBL] [Abstract][Full Text] [Related]
8. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
Suh DC; Lau H; La HO; Choi IS; Geba GP
Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
[TBL] [Abstract][Full Text] [Related]
9. Definitions of exacerbations: does it really matter in clinical trials on COPD?
Effing TW; Kerstjens HAM; Monninkhof EM; van der Valk PDLPM; Wouters EFM; Postma DS; Zielhuis GA; van der Palen J
Chest; 2009 Sep; 136(3):918-923. PubMed ID: 19736196
[TBL] [Abstract][Full Text] [Related]
10. Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients.
Bu XN; Yang T; Thompson MA; Hutchinson AF; Irving LB
Singapore Med J; 2011 Dec; 52(12):894-900. PubMed ID: 22159933
[TBL] [Abstract][Full Text] [Related]
11. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
12. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary.
Leidy NK; Wilcox TK; Jones PW; Roberts L; Powers JH; Sethi S;
Am J Respir Crit Care Med; 2011 Feb; 183(3):323-9. PubMed ID: 20813886
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological relationships between the common cold and exacerbation frequency in COPD.
Hurst JR; Donaldson GC; Wilkinson TM; Perera WR; Wedzicha JA
Eur Respir J; 2005 Nov; 26(5):846-52. PubMed ID: 16264045
[TBL] [Abstract][Full Text] [Related]
14. Validity of an automated telephonic system to assess COPD exacerbation rates.
Bischoff EW; Boer LM; Molema J; Akkermans R; van Weel C; Vercoulen JH; Schermer TR
Eur Respir J; 2012 May; 39(5):1090-6. PubMed ID: 21920893
[TBL] [Abstract][Full Text] [Related]
15. Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.
Anzueto A; Miravitlles M; Ewig S; Legnani D; Heldner S; Stauch K
Respir Med; 2012 Sep; 106(9):1258-67. PubMed ID: 22749710
[TBL] [Abstract][Full Text] [Related]
16. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.
Casanova C; de Torres JP; Aguirre-Jaíme A; Pinto-Plata V; Marin JM; Cordoba E; Baz R; Cote C; Celli BR
Am J Respir Crit Care Med; 2011 Nov; 184(9):1015-21. PubMed ID: 21836135
[TBL] [Abstract][Full Text] [Related]
17. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year.
Xu W; Collet JP; Shapiro S; Lin Y; Yang T; Wang C; Bourbeau J
Eur Respir J; 2010 May; 35(5):1022-30. PubMed ID: 19897555
[TBL] [Abstract][Full Text] [Related]
18. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.
Yu AP; Yang H; Wu EQ; Setyawan J; Mocarski M; Blum S
J Med Econ; 2011; 14(3):315-23. PubMed ID: 21500975
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
20. COPD exacerbations: definitions and classifications.
Burge S; Wedzicha JA
Eur Respir J Suppl; 2003 Jun; 41():46s-53s. PubMed ID: 12795331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
